Gilead Sciences, Inc. $GILD Shares Sold by Integrated Advisors Network LLC

Integrated Advisors Network LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 72.4% in the first quarter, HoldingsChannel.com reports. The firm owned 2,160 shares of the biopharmaceutical company’s stock after selling 5,666 shares during the quarter. Integrated Advisors Network LLC’s holdings in Gilead Sciences were worth $301,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Kiley Juergens Wealth Management LLC acquired a new position in Gilead Sciences during the first quarter worth about $235,000. Canvas Wealth Advisors LLC acquired a new position in Gilead Sciences during the first quarter worth $215,000. O Domhnaill Enterprises Inc. purchased a new stake in Gilead Sciences during the first quarter worth $2,118,000. Walser Wealth Management Company A Ltd Liability Co boosted its position in Gilead Sciences by 7.6% during the first quarter. Walser Wealth Management Company A Ltd Liability Co now owns 1,905 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 135 shares in the last quarter. Finally, Hodges Capital Management Inc. grew its holdings in Gilead Sciences by 1.7% in the first quarter. Hodges Capital Management Inc. now owns 8,718 shares of the biopharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 146 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 3.7%

Shares of Gilead Sciences stock traded down $5.01 during trading hours on Friday, reaching $129.83. 5,934,235 shares of the company’s stock were exchanged, compared to its average volume of 7,886,756. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29. The company has a fifty day moving average of $129.78 and a 200-day moving average of $134.96. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $161.19 billion, a price-to-earnings ratio of 17.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period in the prior year, the firm posted $1.81 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,000 shares of company stock worth $10,824,500 in the last three months. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GILD. Royal Bank Of Canada cut their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a report on Monday, July 6th. Citigroup lifted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Twenty-six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $159.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.